Business Standard
Monday, Nov 23, 2009
 
drived banner
drived banner
  Advanced Search
Feedback | RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Smart Portfolios II
  Search:

Aurobindo gets Health Canada nod for gabapentin
BS Reporter / Hyderabad January 6, 2009, 12:01 IST

Aurobindo Pharma, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has received approval from Health Canada -- a department of the Canadian government with responsibility for national public health -- for its abbreviated new drug submission Gabapentin capsules in 100mg, 300mg and 400mg strengths.

 
 
News Now
Paper
Specials
- Sensex makes remarkable recovery, regains 17K
- Range-trading may continue this week
- US sleuths believe ISI had links with Headley
- India not worried about US honouring n-deal: PM
- Vendata expects quick nod for Orissa project
More  

This is Aurobindo's sixth approval from Health Canada.

Gabapentin capsules 100mg, 300mg and 400mg is the generic equivalent of Pfizer Canada Inc's Neurontin capsules 100mg, 300mg and 400mg, which falls under the central nervous system (CNS) segment indicated for the treatment of seizures in patients diagnosed with epilepsy, the company stated in a press release on Tuesday.

Arrow Other Stories     
- Sensex makes remarkable recovery, regains 17K
- L N Mittal doubles his stake in Ophir Energy
- Indian handicraft firms to participate in Munich fair
- Microsoft eyes Indian smartphone mkt
- RIL Hazira unit bags 'Excellent Energy Efficient Unit Award'
More  
  Read Business news in 
  Get financial advisory and solutions for your projects
  Holidays starting at a delightful EMI of Rs 3481
  Switch on and say hello to Monday morning !
  Your dream home can now be a reality.
  Visit Fortis for a preventive health check-up & get a 20% discount.
  Follow the ups and downs of your investments. Try our new Portfolio Tracker
  Kolkata Dock \ Freight contract for the British Gurkhas Nepal
  Find how Midsize Businesses use ERP to gain competitive advantage
  Trading in Forex is now as easy as 1-2-3
  Discover an economical and cost effective way to market your products and services
  Giftwithlove.com: Same day delivery of Flowers and Cakes to India
  Download the E-book on the Future of Business Intelligence
  Learn Best Practices for improving customer satisfaction
  Know your customers better... download the free e-book on CRM
   Discussion Board / User Comments    
Display Name  Email-Id  
Post your comment
Most Popular
Read
E-Mailed
Commented
   
- Indian CIOs more progressive than global counterparts: IBM study
- IAF orders more Tejas LCAs to replace MiG-21s
- High carryover and potential for breakouts
- Range-trading may continue this week
- Ubuntu 9.10: A karmic disconnection
 
 More  
BS Poll
Cast Your Vote
 
   
 
Should India's defence sector be thrown open to foreign investments?
  Yes  No
Submit

  Hot Searches  
 
Amitabh Bachchan | N Chandrasekaran | Swine Flu | Mukesh Ambani | Anil Ambani | TCS | Infosys |  Air India |  Duronto |  Pranab Mukherjee | Sonia Gandhi | Congress | Rahul Gandhi |  Bigg Boss |  New Pension Scheme |  Service tax |  Excise duty |  Sebi | Tech Mahindra |  Ramalinga Raju |  Satyam |  Reliance  |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  |  B-School | DLF  Sensex |  Tax calculator | Home Loan  | Bollywood | Personal Finance |  inflation | oil prices |  World Bank | Reliance Infratel |  HDFC |  Barack Obama  
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Site Map | Contact Us | Feedback